Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation
Ixekizumab, tofacitinib, and golimumab are all cost-effective options for PsA. These findings support phenotype-guided therapeutic decisions and highlight the influence of drug pricing.
Authors
- Estefanía Pardo
- Stefanie Burger (ORCID: https://orcid.org/0009-0003-4827-8829)
- Paula Alvarez (ORCID: https://orcid.org/0009-0000-0795-4307)
- Rubén Queiro
- Ignacio Braña
- Marta Loredo
Institutions
- Universidad de Oviedo (ES)
- Hospital Universitario Central de Asturias (ES)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1080/14737167.2026.2629351
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00